All News

Early identification of psychosocial problems and psychotherapeutic care are critical in mitigating issues of low self-esteem and psychosocial maladjustment in children with growth hormone deficiency (GHD).

The approach works by transforming the condition of normal and tumor cells into a highly proliferative “reprogrammed stem-like” condition that still has the original karyotypes.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

New study results indicate that initiation of a diet intended to lower blood pressure could benefit migraineurs.

CVS announces it will close around 900 stores; states in the upper Midwest are suffering another COVID-19 surge; Biden increases federal waterway protection.

Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, discusses current and emerging therapeutic and technological advancements in the management of Fabry disease.

A re-evaluation of patients found most had intermediate lupus erythematosus, even though the vast majority were initially diagnosed with the limited-cutaneous form of the disease.

Cynthia Rice, JDRF chief mission strategy officer, discusses how JDRF is working to make automated insulin delivery available and affordable for everyone.

Adherence to antiretroviral treatment (ART) for HIV among Black sexual minority men who have sex with men remains below that of their White counterparts, as does the resulting viral suppression.

A recent review provides insight into the clinical progression of treatment-naive patients with spinal muscular atrophy type 3 who have lost ambulation.

Patients with nonalcoholic steatohepatitis (NASH) and obesity had a reduced risk of major adverse liver outcomes and major adverse cardiovascular (CV) events after they underwent bariatric surgery compared with patients who did not have surgery.

The European Commission gave its stamp of approval for Vumerity (diroximel fumarate), developed by Biogen, as an oral treatment for patients with relapsing-remitting multiple sclerosis (RRMS).

Using cell cultures from pediatric patients with neuroblastoma, researchers performed drug-response testing and investigated correlations between copy number and cytotoxicity of drug treatment.

Patients with asthma were found to have a more than 3-fold greater risk of developing narcolepsy than those without asthma, with use of inhaled corticosteroids indicated to decrease risk.

Moderna requests an EUA for its COVID-19 booster for all adults; the Securities and Exchange Commission (SEC) is investigating claims regarding data for Cassava Sciences’ Alzheimer drug; Florida legislators approved a bill barring private companies from issuing COVID-19 vaccine mandates.

Investigators drew insights about consumers’ health care shopping behavior by analyzing use of an online price transparency tool.

Wanting more data on the benefits of sacubitril/valsartan vs renin angiotensin system inhibitor background therapy, investigators conducted a large randomized study among persons with heart failure with preserved ejection fraction (HFpEF).

Zhonglin Hao, MD, PhD, of the Markey Cancer Center at the University of Kentucky, answers questions about recently approved therapies in small cell lung cancer (SCLC) and current trials examining new treatment options.

The guideline reflects findings regarding confidence in evidence about how to care for the motor symptoms in patients with early Parkinson disease (PD), including the comparative efficacy of treatments as well as the comparative risk of adverse events.

Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences, explains efficacy and safety implications of JAK inhibitor use for atopic dermatitis.

The forum will focus on PBMs’ disproportionate influence over the treatment of patients with cancer, as well as drug pricing and patient cost sharing.

Writing in The Lancet, researchers discuss disparities in type 1 diabetes care on the 100th anniversary of the discovery of insulin.

Data outline prevalence of COVID-19 breakthrough and long haul infections among patients with rheumatic diseases.

Pfizer has granted a second license to allow its COVID-19 pill to be manufactured and sold in developing countries; a bipartisan group argues against the No Surprises Act; the battle over the 340B discount program continues.

Phase 3 findings of the DISCOVER-2 trial presented at the 2021 American College of Rheumatology Annual Meeting indicated that guselkumab (Tremfya) provided long-term improvement in joint manifestations, disease activity, and physical function among patients with psoriatic arthritis who had no prior biologic treatment.

Anti-CD20 disease-modifying therapies, including rituximab and ocrelizumab, were found to increase the risk of hospitalization and intensive care unit admission in patients with multiple sclerosis (MS) who develop COVID-19, investigators concluded in this new study.

Pain and fear/anxiety were the most common barriers to anti–vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration and diabetic macular edema. Another study found that those conditions had a significant impact on patients’ quality of life and Medicare costs.

The findings showed that between 2009 to 2016, 76% of the 122 patients included in the study were on sick leave a year following their allogeneic hematopoietic stem cell transplantation (allo-HSCT).